- SCYNEXIS press release ( NASDAQ: SCYX ): Q2 GAAP EPS of -$0.31 beats by $0.28 .
- Revenue of $1.32M misses by $0.32M .
- Cash and cash equivalents totaled $118.7 million on June 30, 2022, compared to $104.5 million in cash and cash equivalents on December 31, 2021.
- Based upon its current operating plan, SCYNEXIS believes that its existing cash and cash equivalents, and the anticipated sales of BREXAFEMME, will enable SCYNEXIS to fund its operating requirements into Q1 2024.
For further details see:
SCYNEXIS GAAP EPS of -$0.31 beats by $0.28, revenue of $1.32M misses by $0.32M